Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models

Chia Chin Wu, Licai Huang, Zhongting Zhang, Zhenlin Ju, Xingzhi Song, E. Anders Kolb, Wendong Zhang, Jonathan Gill, Min Ha, Malcolm A. Smith, Peter Houghton, Christopher L. Morton, Raushan Kurmasheva, John Maris, Yael Mosse, Yiling Lu, Richard Gorlick, P. Andrew Futreal, Hannah C. Beird

Research output: Contribution to journalArticlepeer-review

Abstract

Osteosarcoma is the most common primary bone malignancy in children and young adults, and it has few treatment options. As a result, there has been little improvement in survival outcomes in the past few decades. The need for models to test novel therapies is especially great in this disease since it is both rare and does not respond to most therapies. To address this, an NCI-funded consortium has characterized and utilized a panel of patient-derived xenograft models of osteosarcoma for drug testing. The exomes, transcriptomes, and copy number landscapes of these models have been presented previously. This study now adds whole genome sequencing and reverse-phase protein array profiling data, which can be correlated with drug testing results. In addition, four additional osteosarcoma models are described for use in the research community.

Original languageEnglish (US)
Article number19891
JournalScientific reports
Volume14
Issue number1
DOIs
StatePublished - Dec 2024

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models'. Together they form a unique fingerprint.

Cite this